World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 16 December 2017
Main ID:  NCT02467322
Date of registration: 04/06/2015
Prospective Registration: No
Primary sponsor: Institute of Liver and Biliary Sciences, India
Public title: To Study The Incidence And Outcome Of Paracentesis Induced Circulatory Dysfunction in Decompensated Cirrhotics Undergoing Less Than 5 Litres Of Ascitic Fluid Tap With Or Without Albumin Infusion.
Scientific title: To Study The Incidence And Outcome Of Paracentesis Induced Circulatory Dysfunction In Decompensated Cirrhotics Undergoing Less Than 5 Litres Of Ascitic Fluid Tap With Or Without Albumin Infusion
Date of first enrolment: February 23, 2015
Target sample size: 80
Recruitment status: Completed
URL:  https://clinicaltrials.gov/show/NCT02467322
Study type:  Interventional
Study design:  Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).  
Phase:  N/A
Countries of recruitment
India
Contacts
Key inclusion & exclusion criteria

Inclusion Criteria:

1. All Cirrhotics decompensated with ascites admitted in the hospital.

2. Grade II/III ascites

3. Need for paracentesis.

Exclusion Criteria:

1. Age <12 or > 75 years

2. Hepatocellular carcinoma

3. Non cirrhotic ascites such as malignancy or tubercular peritonitis

4. Serum Cr >1.5mg%

5. Refractory septic shock

6. Grade III/IV hepatic encephalopathy

7. Abdominal wall cellulitis

8. Active variceal bleed

9. Respiratory, cardiac and renal failure

10. Refusal to participate in the study



Age minimum: 18 Years
Age maximum: 75 Years
Gender: All
Health Condition(s) or Problem(s) studied
Decompensated Cirrhosis
Intervention(s)
Drug: Albumin
Drug: ascitic fluid
Primary Outcome(s)
Incidence of PICD (Paracentesis Induced Circulatory Dysfunction). [Time Frame: 1 Year]
Secondary Outcome(s)
Changes in aldosterone with volume of ascitic fluid tap. [Time Frame: 1 year]
Survival [Time Frame: 28 days]
Changes in plasma Renin activity. [Time Frame: 1 Year]
Total number of patients develop Hepatorenal Syndrome. [Time Frame: 1 Year]
Total number of patients develop hyponatremia. [Time Frame: 1 Year]
Secondary ID(s)
ILBS-Cirrhosis-003
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history